A newly discovered peptide could rival Ozempic — but with fewer side effects and a more targeted approach to weight loss.
Stanford Medicine
Scientists at Stanford Medicine have identified a naturally occurring molecule that appears to mimic some of the weight loss effects of semaglutide, the drug widely known as Ozempic. In animal studies, the molecule reduced appetite and body weight while avoiding several common side effects such as nausea, constipation, and muscle loss.
The molecule, called BRP, works through a different but
related biological pathway and activates distinct groups of neurons in the
brain. This suggests it may offer a more precise way to control appetite and
metabolism.
"The receptors targeted by semaglutide are found in the
brain but also in the gut, pancreas and other tissues," said assistant
professor of pathology Katrin Svensson, PhD. "That's why Ozempic has
widespread effects including slowing the movement of food through the digestive
tract and lowering blood sugar levels. In contrast, BRP appears to act
specifically in the hypothalamus, which controls appetite and metabolism."
Svensson, the senior author of the study published in Nature,
has also co-founded a company that plans to begin human clinical trials in the
near future. The study's lead author is senior research scientist Laetitia
Coassolo, PhD.
















